D. Scott Edwards, PhD

Chief Development Officer

D. Scott Edwards, PhD, brings to OcuTerra Therapeutics an extensive background in pharmaceutical research and development with a record of major accomplishments in the areas of small molecule therapeutics and medical imaging contrast agents. He held a basic research position at Dow Chemical Company from 1983 through 1987 and then began his career in drug discovery and development after joining the medical imaging division of DuPont Pharmaceutical Co. in 1988. At DuPont and Bristol-Myers Squibb, he held positions of increasing responsibility spanning discovery, pre-clinical development, clinical development and regulatory affairs resulting in multiple new drug approvals and the first pediatric extension for an imaging drug. Scott joined OcuTerra Therapeutics in 2012 where he leads the drug development efforts including the clinical, regulatory, and quality functions and manages the company's expansive patent estate. He has managed external resourcing, conducting critical toxicology studies, manufacturing clinical drug supplies, and submitting regulatory filings. Scott has worked closely with our Scientific Advisory Board of retina specialists on the design, conduct, and interpretation of the Phase I/II studies and the development of a comprehensive clinical development plan for OTT166.

He holds a bachelor’s in chemistry from the Georgia Institute of Technology and a PhD in Organometallic Chemistry from the Massachusetts Institute of Technology. He is an inventor on 27 U.S. Patents and an author on 75 publications